Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vaqta Generic Name & Formulations
Legal Class
Rx
General Description
Hepatitis A vaccine, inactivated 25Units per 0.5mL (pediatric/adolescent), or 50Units per 1mL (adult); susp for IM inj; aluminum adsorbed; preservative-free.
How Supplied
Prefilled syringes (0.5mL, 1mL)—1, 5; Single-dose vials (0.5mL)—1, 10; Single-dose vials (1mL)—1, 5, 10
Manufacturer
Vaqta Indications
Indications
Hepatitis A immunization.
Vaqta Dosage and Administration
Adult
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later.
Children
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later.
Vaqta Contraindications
Not Applicable
Vaqta Boxed Warnings
Not Applicable
Vaqta Warnings/Precautions
Warnings/Precautions
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers.
Vaqta Pharmacokinetics
See Literature
Vaqta Interactions
Interactions
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature.
Vaqta Adverse Reactions
Adverse Reactions
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects.
Vaqta Clinical Trials
See Literature
Vaqta Note
Not Applicable
Vaqta Patient Counseling
See Literature
